Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Period: Quarterly report (Form 10-Q) for the period ended June 30, 2010.
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics. The company has no commercial products and generates no revenue.
Key Focus: Primary focus is on the development of eniluracil (a DPD inhibitor) in combination with 5-FU and leucovorin. The company is also supporting Phase III trials for STS (a chemoprotectant) via third-party collaborators and has terminated its license for ADH-1.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,935,000) | $(3,184,000) |
| Operating Expenses | $2,943,000 | $2,913,000 |
| Research & Development | $309,000 | $1,929,000 |
| General & Administrative | $2,563,000 | $984,000 |
| Cash and Cash Equivalents (End of Period) | $7,152,000 | $1,540,000 |
| Net Cash Used in Operating Activities | $(723,000) | $(3,833,000) |
| Accumulated Deficit | $(103,926,000) | $(97,979,000) |
| Working Capital | $6,786,000 | $413,000 (Dec 31, 2009) |
Debt and Liabilities: Total liabilities increased to $7,632,000, driven primarily by a $7,262,000 derivative warrant liability. Current liabilities were $370,000. There is no long-term debt.
Material Changes vs. Prior Period
- Financing Activity: In April 2010, the company completed a private placement raising net proceeds of $7,190,000. This resulted in a significant increase in cash from $685,000 (Dec 31, 2009) to $7,152,000 (June 30, 2010).
- Derivative Liability: A new derivative warrant liability of $7,262,000 was recorded due to the issuance of 240 million warrants denominated in Canadian dollars. This created an unrealized loss of $72,000 for the period.
- Expense Composition: While total operating expenses remained relatively flat year-over-year ($2.94M vs $2.91M), the composition shifted drastically. R&D expenses decreased by 84% ($1.62M reduction) due to program prioritization. Conversely, G&A expenses increased by 161% ($1.58M increase), primarily due to $2.05M in stock-based compensation related to new executive and board grants.
- Share Count: Common shares outstanding increased from 128.2 million to 368.3 million following the private placement.
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes a "Going Concern" warning. Despite the recent financing, the company has an accumulated deficit of over $103 million and requires additional funding to continue operations. Failure to secure capital could force a curtailment of activities.
- Clinical Outlook: Management plans to commence a Phase II study for eniluracil/5-FU/leucovorin in metastatic breast cancer within six months. Patient enrollment continues for STS Phase III trials managed by SIOPEL and the Children's Oncology Group.
- Internal Controls: Management identified two material weaknesses in internal controls: (1) lack of segregation of duties (one person performs all accounting duties) and (2) insufficient personnel with technical accounting knowledge. Remediation is dependent on securing additional financial resources.
- Listing Status: The company faced a delisting review by the Toronto Stock Exchange but was notified in August 2010 that it satisfied listing requirements.
Investor Verification Checklist
- Cash Runway: Verify if the $7.15M cash balance is sufficient to fund the planned Phase II eniluracil trial and ongoing operations without immediate dilution or debt.
- Derivative Liability Impact: Assess the volatility of the $7.26M warrant liability and its potential to cause future non-cash losses or gains based on stock price and currency fluctuations.
- Stock-Based Compensation: Review the $2.05M stock-based compensation expense and the dilution impact of the 67.7 million options issued to employees and directors in August 2010 (post-period).
- Internal Control Remediation: Monitor the company's ability to hire qualified accounting staff to address the material weaknesses in financial reporting.
- Collaborator Dependence: Confirm the status and funding commitments of the SIOPEL and Children's Oncology Group for the STS Phase III trials, as the company relies on them for trial execution.